Literature DB >> 17465720

IL-19 and IL-20: two novel cytokines with importance in inflammatory diseases.

Robert Sabat1, Elizabeth Wallace, Stefanie Endesfelder, Kerstin Wolk.   

Abstract

IL-19 and IL-20 are two cytokines that were discovered in 2000 and 2001, respectively. Based on the structure and location of their genes, their primary and secondary protein structures and the used receptor complexes, they were classified with IL-10, IL-22, IL-24, IL-26, IL-28 and IL-29 in the IL-10 family of cytokines, and form a subgroup with IL-24 within this family. IL-19 and IL-20 are produced by monocytes as well as non-immune tissue cells under inflammatory conditions. IL-19 and IL-20 act via a receptor complex that consists of the IL-20R1 and IL-20R2 chains. IL-20 is additionally able to signal via a second receptor complex (IL-22R1/IL-20R2). It is controversial whether or not IL-19 and IL-20 regulate the function of immune cells. However, the expression of their receptors aliments the perception that the cells of the skin, lungs and reproductive organs as well as various glands are major targets of these mediators. Results from animal experiments and massively increased expression of these mediators in human inflamed tissues support the assumption that they play an important role in the pathogenesis of a few inflammatory diseases. For this reason, the authors have reviewed the facts known at present regarding these cytokines and postulate that IL-19 and IL-20 are pharmacologically interesting distal elements of an inflammatory cascade.

Entities:  

Mesh:

Substances:

Year:  2007        PMID: 17465720     DOI: 10.1517/14728222.11.5.601

Source DB:  PubMed          Journal:  Expert Opin Ther Targets        ISSN: 1472-8222            Impact factor:   6.902


  33 in total

1.  Cardiac aging is initiated by matrix metalloproteinase-9-mediated endothelial dysfunction.

Authors:  Andriy Yabluchanskiy; Yonggang Ma; Ying Ann Chiao; Elizabeth F Lopez; Andrew P Voorhees; Hiroe Toba; Michael E Hall; Hai-Chao Han; Merry L Lindsey; Yu-Fang Jin
Journal:  Am J Physiol Heart Circ Physiol       Date:  2014-03-21       Impact factor: 4.733

Review 2.  New players in cytokine control of HIV infection.

Authors:  Massimo Alfano; Andrea Crotti; Elisa Vicenzi; Guido Poli
Journal:  Curr HIV/AIDS Rep       Date:  2008-02       Impact factor: 5.071

3.  Gene expression profiling in autoimmune noninfectious uveitis disease.

Authors:  Zhuqing Li; Baoying Liu; Arvydas Maminishkis; Sankaranarayana P Mahesh; Steven Yeh; Julie Lew; Wee Kiak Lim; H Nida Sen; Grace Clarke; Ronald Buggage; Sheldon S Miller; Robert B Nussenblatt
Journal:  J Immunol       Date:  2008-10-01       Impact factor: 5.422

4.  Attenuation of experimental atherosclerosis by interleukin-19.

Authors:  Stephen Ellison; Khatuna Gabunia; Sheri E Kelemen; Ross N England; Rosario Scalia; James M Richards; A Wayne Orr; Wayne Orr; James G Traylor; Thomas Rogers; William Cornwell; Lisa M Berglund; Isabel Goncalves; Maria F Gomez; Michael V Autieri
Journal:  Arterioscler Thromb Vasc Biol       Date:  2013-08-15       Impact factor: 8.311

5.  Interleukin-19 increases angiogenesis in ischemic hind limbs by direct effects on both endothelial cells and macrophage polarization.

Authors:  James Richards; Khatuna Gabunia; Sheri E Kelemen; Farah Kako; Eric T Choi; Michael V Autieri
Journal:  J Mol Cell Cardiol       Date:  2014-11-08       Impact factor: 5.000

6.  Treatment with IL-19 improves locomotor functional recovery after contusion trauma to the spinal cord.

Authors:  Jidong Guo; Huadong Wang; Li Li; Yanli Yuan; Xiuxiu Shi; Shuxun Hou
Journal:  Br J Pharmacol       Date:  2018-05-22       Impact factor: 8.739

7.  IL-22 Signaling in the Tumor Microenvironment.

Authors:  Runqiu Jiang; Beicheng Sun
Journal:  Adv Exp Med Biol       Date:  2021       Impact factor: 2.622

8.  Interleukin-19 can enhance angiogenesis by Macrophage Polarization.

Authors:  Khatuna Gabunia; Michael V Autieri
Journal:  Macrophage (Houst)       Date:  2015

9.  Interleukin-19 contributes as a protective factor in experimental Th2-mediated colitis.

Authors:  Yasuyuki Fujimoto; Yasu-Taka Azuma; Yukiko Matsuo; Mitsuru Kuwamura; Nobuyuki Kuramoto; Mariko Miki; Naoki Azuma; Midori Teramoto; Kazuhiro Nishiyama; Takeshi Izawa; Hidemitsu Nakajima; Tadayoshi Takeuchi
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  2016-12-09       Impact factor: 3.000

Review 10.  Interleukin-10: new perspectives on an old cytokine.

Authors:  David M Mosser; Xia Zhang
Journal:  Immunol Rev       Date:  2008-12       Impact factor: 12.988

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.